Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intertransverse Process Block for Minor Breast Cancer Surgery – Single vs Multiple Injection
2022-501312-34-00Phase 4Withdrawn
- Sponsor
- Zealand University Hospital
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ropivacaine in breast cancer (2 arms), sponsored by Zealand University Hospital. Primary endpoint: Number of anaesthetised thoracic dermatomes. Planned start Oct 2022; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-501312-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501312-34-00.